2023年の欧州ブランドジェネリック市場の規模、トレンド、成長レポート

欧州ブランドジェネリック医薬品市場規模、シェア、トレンド分析レポート

Market Size in USD Billion

CAGR : 4.50 %

USD 67.97 Billion USD 96.49 Billion 2024 2032

予測期間	2025 –2032
市場規模（基準年）	USD 67.97 Billion
Market Size (Forecast Year)	USD 96.49 Billion
CAGR	4.50 %
Major Markets Players	Teva Pharmaceutical Industries Ltd. Viatris Inc. Sandoz Group AG Dr. Reddy’s Laboratories Ltd. Sun Pharmaceutical Industries Ltd.

欧州ブランドジェネリック医薬品市場セグメンテーション：薬物クラス別（降圧剤、ホルモン剤、代謝拮抗剤、脂質低下薬、抗てんかん薬、アルキル化剤、抗うつ剤、抗精神病薬、その他）、用途別（心血管疾患、疼痛管理・抗炎症薬、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他）、投与経路別（経口、注射、局所投与、その他）、製品タイプ別（付加価値ブランドジェネリック医薬品、商品名ジェネリック医薬品）、患者層別（成人、高齢者、小児）、エンドユーザー別（病院、診療所、在宅ケア、学術研究機関、その他）、流通チャネル別（小売薬局、病院薬局、直接入札、その他） - 2032年までの業界動向と予測

欧州のブランドジェネリック医薬品市場規模

ヨーロッパのブランドジェネリック医薬品市場は2024年に679億7000万米ドルと評価され、 2032年までに964億9000万米ドルに達すると予想されています。
2025年から2032年の予測期間中、市場は4.5％のCAGRで成長すると予想されます。これは主に、医療費の増加、慢性疾患の罹患率の上昇、先進国と新興国市場の両方における手頃な価格で高品質の医薬品の需要に牽引されています。
この成長は、先発医薬品の特許満了、費用対効果の高い治療を支援する政府の政策、新興国における医療アクセスの拡大、デジタルヘルスおよびeファーマシーチャネルの普及拡大によってさらに促進されています。医薬品処方の継続的な革新、患者アドヒアランス戦略の改善、大手製薬会社によるブランドジェネリック医薬品ポートフォリオの拡大も、世界的な市場拡大を加速させると予想されます。

欧州ブランドジェネリック医薬品市場分析

欧州のブランドジェネリック医薬品市場は、ジェネリック医薬品の手頃な価格とブランド認知度を兼ね備えた、費用対効果が高く高品質な医薬品への需要の高まりに牽引され、力強い成長を遂げています。ブランドジェネリック医薬品は、患者の服薬アドヒアランスの向上、必須医薬品へのアクセス拡大、そして新興市場と先進市場の両方において製薬会社への収益機会の提供において重要な役割を果たしています。市場は、国による規制の違い、価格圧力、そしてブランドロイヤルティを維持するための継続的なイノベーションの必要性といった課題に直面しています。
慢性疾患管理、腫瘍学、心血管疾患、感染症治療の各分野が主要な成長ドライバーとなっています。新興国における非感染性疾患の罹患率の上昇、医療意識の高まり、そして医療へのアクセス拡大は、ブランドジェネリック医薬品の需要を押し上げています。さらに、バイオシミラーやスペシャリティジェネリック医薬品の普及拡大は、有効性と安全性を維持しながら、高価な先発医薬品の代替品を提供することで、市場のダイナミクスを形成しています。製薬会社は、マーケティング戦略、患者教育、戦略的パートナーシップを活用し、ブランドジェネリック医薬品の普及を促進しています。
ドイツは、英国とイタリアに先導され、この地域の確立されたジェネリック医薬品製造能力、有利な政府政策、そして医療費の増加により、市場を支配しています。北米は、慢性疾患治療への高い需要、医療保険適用範囲の拡大、そして強力な流通ネットワークに牽引され、これに続いています。ヨーロッパは、ジェネリック医薬品代替政策、コスト抑制策、そして医療効率への重点の高まりに支えられ、着実な成長を遂げています。ラテンアメリカ、中東、アフリカの新興市場では、医療インフラの改善、規制の整合性の向上、そして医薬品製造能力の向上により、ジェネリック医薬品の導入が徐々に進んでいます。
降圧剤分野は、簡便な投与量、費用対効果、および治療領域全体にわたる幅広い適用性に対する患者の好みにより、22.51%の市場シェアで市場を支配すると予想されています。

レポートの範囲と欧州ブランドジェネリック医薬品市場のセグメンテーション

属性	欧州ブランドジェネリック医薬品の主要市場分析
対象セグメント	薬剤クラス別：降圧剤、ホルモン剤、代謝拮抗剤、脂質低下剤、抗てんかん剤、アルキル化剤、抗うつ剤、抗精神病薬、その他用途別：心血管疾患、疼痛管理および抗炎症、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他投与経路：経口、注射、局所投与、その他製品タイプ別:付加価値ブランドジェネリック、商品名ジェネリック患者属性別：成人、高齢者、小児エンドユーザー別:病院、診療所、在宅ケア、学術研究機関、その他流通チャネル別：小売薬局、病院薬局、直接販売、その他
対象国	ヨーロッパドイツフランス英国イタリアスペインロシア七面鳥ベルギーオランダスイスデンマークスウェーデンポーランドノルウェーフィンランドその他のヨーロッパ
主要な市場プレーヤー	テバ製薬工業株式会社（イスラエル） Viatris Inc.（米国）サンドスグループAG（スイス） Dr. Reddy's Laboratories Ltd.（インド）サン・ファーマシューティカル・インダストリーズ（インド）オーロビンドファーマ（インド）シプラ・ファーマシューティカルズ（インド）フレゼニウス・カビ（ドイツ）アボット（米国）グレンマーク・ファーマシューティカルズ（インド）ヒクマ・ファーマシューティカルズPLC（英国）ルピン・ファーマシューティカルズ（インド）エムキュア・ファーマシューティカルズ（インド）バウシュ・ヘルス・カンパニーズ（カナダ）マンカインドファーマ（インド）ジュビラント・ファーマ（インド）ナトコファーマ（インド）アリスト・ファーマシューティカルズ・プライベート・リミテッド（インド）バイオコン・リミテッド（インド）トレント・ファーマシューティカルズ社（インド）エンドー株式会社（米国）アレンビック・ファーマシューティカルズ・リミテッド（インド） SAGENT Pharmaceuticals（米国）パナセアバイオテック（インド）
市場機会	新興市場におけるブランドジェネリック医薬品の拡大主要医薬品の特許崖専門分野および複合ジェネリック医薬品への進出
付加価値データ情報セット	Data Bridge Market Research がまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、専門家による詳細な分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

欧州のブランドジェネリック医薬品市場動向

「手頃な価格で高品質な医薬品への需要の高まりが欧州のブランドジェネリック医薬品市場の成長を牽引」

医療費の高騰、人口の高齢化、そして慢性疾患や生活習慣病の罹患率の上昇は、手頃な価格でありながら高品質な医薬品に対するヨーロッパの需要を高め、ブランドジェネリック医薬品の成長を支えています。ブランドジェネリック医薬品は、有効性と安全性の高水準を維持しながら、先発医薬品に代わる費用対効果の高い代替品を提供することから、先進国市場と新興国市場の両方で不可欠な存在となっています。
政府と医療保険者は、医療費の抑制、治療へのアクセス拡大、患者の服薬遵守の向上を目的として、政策、償還枠組み、ジェネリック医薬品代替プログラムなどを通じて、ブランドジェネリック医薬品の使用を積極的に推進しています。これらの施策は、心血管疾患、糖尿病、腫瘍学、中枢神経系疾患など、複数の治療領域における市場導入を促進しています。
例えば、2024年3月、米国FDAは糖尿病や高血圧といった需要の高い治療領域において、複数の新しいブランドジェネリック製剤を承認しました。これは、ブランド医薬品に代わる費用対効果の高い代替品に対するパイプライン活動と規制当局の支援の増加を示しています。これは、患者と医療制度のニーズに応えて、欧州のブランドジェネリック医薬品市場が継続的に拡大していることを示しています。
新興国、特にドイツとラテンアメリカでは、医療インフラの拡充、中流階級人口の増加、そして治療へのアクセス向上を目指す政府の取り組みにより、ブランドジェネリック医薬品の普及が加速しています。企業はこれらの地域で高まる需要に対応するため、現地生産の拡大、研究開発への投資、流通ネットワークの強化に取り組んでいます。
欧州の医療制度が手頃な価格、アクセスしやすさ、治療の遵守を重視し続けるにつれて、ブランドジェネリックの役割は、製造、パッケージング、患者中心の医薬品開発におけるイノベーションを推進しながら持続可能な医療提供を確保する上でますます重要になります。

欧州のブランドジェネリック医薬品市場の動向

ドライバ

「ブロックバスター医薬品の特許切れ」

ブロックバスター医薬品の特許満了が迫っていることは、欧州ブランドジェネリック医薬品市場の拡大を牽引する最も強力な構造的要因の一つです。収益性の高いイノベーター医薬品が独占権を失うと、ジェネリック医薬品メーカーやバイオシミラーメーカーが競合製品を投入する機会が生まれ、イノベーター医薬品の市場シェアは低下し、需要はより低コストの代替品へと向かうことになります。
この「特許の崖」は、下流で連鎖的な影響を引き起こします。製薬会社は略式新薬申請（ANDA）またはバイオシミラー申請を急いで提出し、規制当局は審査を迅速化し、支払者はジェネリック医薬品をますます好むようになり、患者はより手頃な価格のブランドジェネリック医薬品にアクセスできるようになります。
過去10年間、大手医薬品メーカーにおける独占権喪失の波は、ジェネリック医薬品の既存メーカーと新規参入企業に繰り返しチャンスをもたらし、価格動向の再構築、ジェネリック医薬品製造における統合促進、新興市場への地理的拡大の加速につながりました。実際、特許切れによって失われる収益規模は、複雑なジェネリック医薬品やバイオシミラーへの投資を経済的に正当化する要因となることがよくあります。
重要なのは、特許の崖のタイミングと予測可能性により、ジェネリック医薬品企業は、独占権の喪失前に、上市を予測し、開発パイプラインに投資し、提携を結び、規制書類を事前に提出するための戦略的計画の期間が与えられることである。
その結果、ブランドジェネリック医薬品セクターは、大型製品の特許満了と密接に結びついた、競争の原動力となる循環的なフロンティアとなる。

抑制/挑戦

「特許訴訟と知的財産リスク」

特許訴訟と知的財産リスクは、欧州のブランドジェネリック医薬品市場にとって大きな制約となっています。特許紛争の複雑さと長期化は、ジェネリック医薬品の市場参入を遅らせ、市場競争を阻害し、医薬品価格の高止まりにつながる可能性があります。
これらの法廷闘争には、使用方法特許や二次特許など、多層的な特許請求が含まれることが多く、ブランド医薬品の独占期間が当初の特許期限を超えて延長される可能性があります。
さらに、特許侵害訴訟への対応にかかる経済的負担は、ジェネリック医薬品メーカー、特に中小企業の市場参入を阻む要因となっています。特許法の進化と、先発医薬品メーカーによる特許ポートフォリオの戦略的活用は、市場動向をさらに複雑化し、世界的にブランドジェネリック市場が形成される可能性を秘めています。
例えば、2025年10月、エコノミック・タイムズは、ハイデラバードに拠点を置くナトコ・ファーマが、脊髄性筋萎縮症の治療薬リスジプラムに関するスイス製薬会社ロシュとの特許紛争に勝訴したと報じた。
これらの法的および財務的な障壁は、メーカーの収益性と患者が手頃な価格の医薬品にアクセスすることの両方に影響を与えます。全体として、特許訴訟と知的財産リスクは、欧州のブランドジェネリック医薬品市場における競争と成長に影響を与える主要な制約要因であり続けています。

欧州ブランドジェネリック医薬品市場の範囲

ヨーロッパのブランドジェネリック医薬品市場は、薬物クラス、用途、投与経路、製品タイプ、患者の人口統計、エンドユーザー、流通チャネルに基づいて、7 つの主要なセグメントに分割されています。

• 薬物クラス別

欧州のブランドジェネリック医薬品市場は、薬剤の種類に基づいて、降圧剤、ホルモン剤、代謝拮抗剤、脂質低下薬、抗てんかん薬、アルキル化剤、抗うつ薬、抗精神病薬、その他に分類されます。2025年には、世界的な心血管疾患の有病率の上昇、高血圧管理に対する意識の高まり、そして患者と医療提供者による費用対効果の高いジェネリック医薬品への嗜好の高まりを背景に、降圧剤セグメントが22.51%の市場シェアで市場を席巻すると予想されています。

降圧剤分野は、固定用量併用療法の継続的な革新、手頃な価格の医薬品を推進する政府の取り組み、新興経済国における医療へのアクセスの拡大により、降圧剤ブランドジェネリックの採用が総合的に促進され、2025年から2032年の予測期間中に7.0%のCAGRで成長することが見込まれています。

• アプリケーション別

用途別に見ると、市場は心血管疾患、疼痛管理・抗炎症、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他に分類されています。2025年には、世界的な心臓関連疾患の有病率の上昇、高齢化人口の増加、そして予防的な心血管ケアへの意識の高まりと、費用対効果の高いブランドジェネリック医薬品の普及により、心血管疾患セグメントが29.30%の市場シェアで市場を席巻すると予想されています。

心臓血管疾患分野は、新興市場の医療制度により必須医薬品へのアクセスが強化され、固定用量併用療法が普及し、継続的な研究開発により心臓血管治療用ブランドジェネリックの有効性と安全性プロファイルが改善されているため、5.9%のCAGRで着実に拡大すると予測されています。

• 投与経路

投与経路に基づき、欧州ブランドジェネリック医薬品市場は、経口、注射、局所投与、その他に分類されます。2025年には、経口投与の利便性、患者コンプライアンスの高さ、経口製剤の広範な入手性、そして他の投与経路に比べて費用対効果が高いことから、経口セグメントが55.87%の市場シェアで市場を席巻すると予想されています。

経口セグメントは、長期投薬を必要とする慢性疾患の増加、自己投与療法の嗜好の高まり、バイオアベイラビリティが向上し患者に優しい設計の革新的な経口製剤の継続的な導入に支えられ、予測期間中に4.7%の加速成長が見込まれます。

• 製品タイプ別

製品タイプ別に見ると、市場は付加価値ブランドジェネリックと商品名ジェネリックに分類されます。2025年には、付加価値ブランドジェネリックが、その優れた有効性、安全性プロファイルの改善、患者中心の処方、そして標準ジェネリックに比べて差別化された治療効果を提供できる能力により、66.87%の市場シェアを獲得し、市場を席巻すると予想されます。

付加価値ブランドジェネリックセグメントは、患者の服薬遵守を改善する処方に対する医療提供者の嗜好の高まり、併用療法の需要の増加、薬物送達技術の継続的な革新、慢性疾患や複雑な疾患の治療における満たされていない医療ニーズへの対応への重点により、重要性が増しており、CAGR 4.6%で成長しています。

• 患者の人口統計別

患者層に基づき、市場は成人、高齢者、小児の3つに分類されます。2025年には、成人層が65.13%の市場シェアを占めると予想されます。これは、成人人口における心血管疾患、糖尿病、高血圧といった慢性疾患や生活習慣病の有病率の高さが、ブランドジェネリック医薬品に対する継続的な需要を牽引しているためです。

成人セグメントは、ヘルスケアに対する意識の高まり、手頃な価格の医薬品へのアクセスの増加、新興経済国における中流階級人口の増加、成人患者の間でより優れた有効性と遵守を提供する付加価値のあるブランドジェネリック医薬品の選好により、年平均成長率4.6%で成長すると予想されています。

• エンドユーザーによる

エンドユーザーに基づいて、市場は病院、診療所、在宅ケア、学術研究機関、その他に分類されます。2025年には、病院セグメントが51.52%の市場シェアで市場を席巻すると予想されます。これは、患者の治療件数の増加、集中治療におけるブランド医薬品や高品質のジェネリック医薬品への需要、そして必須医薬品の安定供給を確保する病院の集中調達慣行などが要因です。

病院セグメントは、病院インフラの拡張、専門病院および多専門病院の増加、慢性疾患および急性疾患による入院の増加、治療成果の向上を目的とした入院患者ケアにおける付加価値のあるブランドジェネリック医薬品の採用増加により、2025年から2032年の間に4.8%という最も高い成長を記録すると予想されています。

• 流通チャネル別

流通チャネルに基づき、市場は小売薬局、病院薬局、直接入札、その他に分類されます。2025年には、小売薬局セグメントが52.52%の市場シェアで市場を席巻すると予想されます。これは、ブランドジェネリック医薬品が小売店を通じて広く入手可能であること、医薬品への利便性の高いアクセスを求める消費者の嗜好、そして都市部と準都市部の両方で薬局チェーンと独立系ドラッグストアが強く存在感を示していることが要因です。

小売薬局セグメントは、セルフメディケーションの傾向の増加、費用対効果の高いブランドジェネリック医薬品の認知度の高まり、薬局ネットワークの拡大、小売チャネルを通じた必須医薬品への手頃な価格でのアクセスを支援する政府の取り組みにより、2025年から2032年の間に4.7%という最も高い成長を記録すると予想されています。

欧州ブランドジェネリック医薬品市場 – 地域分析

手頃な価格でありながら高品質の医薬品に対する強い需要と、地域全体での医療費の増加により、ドイツは2025年に18.75%という最大の収益シェアでヨーロッパのブランドジェネリック医薬品市場を支配すると予想されています。
この拡大は、医療インフラに対する政府の支援の増加、慢性疾患の蔓延の増加、治療遵守に関する意識の高まりによって推進されており、これらすべてがブランドジェネリック医薬品の採用を促進しています。
ドイツ、フランスなどの国々は、確立された医薬品製造能力、ジェネリック医薬品に対する規制支援、国内のヘルスケア生産への投資増加により、この地域をリードしています。
さらに、現地での医薬品生産、医療へのアクセス、医薬品の輸出を促進する有利な政策により、ドイツにおける市場の成長がさらに加速します。

欧州ブランドジェネリック医薬品市場インサイト

ヨーロッパは、充実した医療制度、ジェネリック医薬品代替政策、そしてコスト抑制への注力により、ブランドジェネリック医薬品市場において引き続き重要な地位を維持しています。ドイツ、フランス、イタリア、英国といった主要経済国は、医療へのアクセスの良さ、スペシャリティジェネリック医薬品の導入拡大、そして慢性疾患管理への投資により、市場を牽引しています。ジェネリック医薬品に対する規制当局の支援に加え、高齢化社会への関心の高まりと手頃な価格の治療法への需要の高まりが、市場の成長をさらに後押ししています。製薬会社、研究機関、そして医療機関間の継続的な連携により、ヨーロッパ大陸全体におけるブランドジェネリック医薬品の継続的なイノベーションと効率的な供給が確保されています。

フランス・ヨーロッパのブランドジェネリック医薬品市場に関する洞察

フランスは、強力な医療インフラ、高度な医薬品製造能力、そして国内医薬品の生産を促進する政府の取り組みに支えられ、欧州のブランドジェネリック医薬品市場において重要な地位を占めています。慢性疾患管理、腫瘍学、そして心血管治療に重点を置くフランスは、ブランドジェネリック医薬品の需要を高めています。さらに、製薬会社と研究機関の戦略的提携は、高付加価値のジェネリック医薬品とスペシャリティ医薬品におけるイノベーションを推進しています。フランスは、医療へのアクセス、手頃な価格、そして治療遵守への関心を高めており、欧州の医薬品業界における同国の重要性をさらに高めています。

スペイン・ヨーロッパのブランドジェネリック医薬品市場に関する洞察

スペインは、医療保険の適用範囲拡大、手頃な価格の治療法への需要増加、慢性疾患管理ソリューションの導入拡大を背景に、欧州のブランドジェネリック医薬品業界において成長市場として台頭しています。医療の近代化、デジタルヘルスへの取り組み、そして地域的な医薬品生産への注力は、ブランドジェネリック医薬品の利用を加速させています。さらに、国内メーカー、研究機関、そして国際的な製薬企業との連携が、高品質なジェネリック医薬品の革新と商業化を支えています。医療インフラへの投資と患者啓発キャンペーンも、市場の着実な成長に貢献しています。

ドイツ・ヨーロッパのブランドジェネリック医薬品市場に関する洞察

ドイツは、医療費の増加、医薬品製造の急速な工業化、慢性疾患および生活習慣病の罹患率の増加に支えられ、予測期間中に最も高いCAGRを記録すると予測されています。インド、中国、日本などの国々は、国内生産能力の拡大、費用対効果の高い医薬品製造、そして支援的な規制政策に牽引され、成長を牽引しています。この地域の強力な医薬品輸出能力、医療アクセスの拡大、そして現地での医薬品生産に向けた取り組みは、市場の成長をさらに加速させています。治療遵守への意識の高まりと、高品質で手頃な価格の医薬品への需要は、ヨーロッパ市場におけるこの地域の優位性を引き続き強化しています。

市場で活動する主要なマーケットリーダーは次のとおりです。

テバ製薬工業株式会社（イスラエル）
Viatris Inc.（米国）
サンドスグループAG（スイス）
Dr. Reddy's Laboratories Ltd.（インド）
サン・ファーマシューティカル・インダストリーズ（インド）
オーロビンドファーマ（インド）
シプラ・ファーマシューティカルズ（インド）
フレゼニウス・カビ（ドイツ）
アボット（米国）
グレンマーク・ファーマシューティカルズ（インド）
ヒクマ・ファーマシューティカルズPLC（英国）
ルピン・ファーマシューティカルズ（インド）
エムキュア・ファーマシューティカルズ（インド）
バウシュ・ヘルス・カンパニーズ（カナダ）
マンカインドファーマ（インド）
ジュビラント・ファーマ（インド）
ナトコファーマ（インド）
アリスト・ファーマシューティカルズ・プライベート・リミテッド（インド）
バイオコン・リミテッド（インド）
トレント・ファーマシューティカルズ社（インド）
エンドー株式会社（米国）
アレンビック・ファーマシューティカルズ・リミテッド（インド）
SAGENT Pharmaceuticals（米国）
パナセアバイオテック（インド）

欧州ブランドジェネリック医薬品市場の最新動向

2025年10月、米国FDAはUZEDY（リスペリドン）徐放性注射懸濁液の適応拡大を承認しました。これにより、成人に加え、13歳から17歳の小児および青年の統合失調症の治療薬としても承認されました。これにより、慢性疾患を抱える若年患者にとって、長期作用型治療の選択肢が提供されます。
2025年8月、テバは米国FDAの承認を取得し、サクセンダ（リラグルチド）注射剤の初のジェネリック医薬品を発売しました。このジェネリックGLP-1受容体作動薬は、成人および小児患者の体重管理ツールとして承認されており、慢性的な体重管理のためのより利用しやすい選択肢を提供します。
2025年8月、ビアトリスは鉄欠乏性貧血の治療薬である鉄スクロース注射剤の初のジェネリック医薬品について、米国FDAの承認を取得しました。この開発により、米国の患者と医療従事者にとって、より手頃な価格の治療選択肢が提供されます。この承認により、ビアトリスのジェネリック注射剤ポートフォリオが強化され、この重要な治療への患者アクセスが向上します。
2025年4月、ビアトリスは、エフェクサー（一般名：ベンラファキシン）の全般性不安障害（GAD）治療薬として、厚生労働省に承認申請を行いました。この承認申請は、日本市場における本剤の治療用途の拡大を目的としています。承認されれば、この疾患に苦しむ日本の患者さんに新たな治療選択肢を提供することになります。

SKU-75016

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

画像をクリックすると拡大します

インタラクティブなデータ分析ダッシュボード
成長の可能性が高い機会のための企業分析ダッシュボード
カスタマイズとクエリのためのリサーチアナリストアクセス
インタラクティブなダッシュボードによる競合分析
最新ニュース、更新情報、トレンド分析
包括的な競合追跡のためのベンチマーク分析のパワーを活用

デモのリクエスト

表のリスト

TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE EUROPE BRANDED GENERICS MARKET

TABLE 2 PATENT LANDSCAPE

TABLE 3 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 10 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 13 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 16 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 17 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 26 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 61 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 62 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 EUROPE PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 78 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 80 EUROPE ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 81 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 83 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 85 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 87 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 EUROPE VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 89 EUROPE TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 90 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 91 EUROPE ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 92 EUROPE GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 93 EUROPE PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 94 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 95 EUROPE HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 96 EUROPE CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 97 EUROPE HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 98 EUROPE ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 99 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 100 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 101 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 102 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 EUROPE HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 104 EUROPE DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 105 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 106 EUROPE BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 107 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 108 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 156 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 167 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 172 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 173 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 GERMANY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 176 GERMANY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 GERMANY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 GERMANY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 GERMANY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 GERMANY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 GERMANY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 GERMANY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 GERMANY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 GERMANY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 GERMANY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 GERMANY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 GERMANY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 GERMANY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 GERMANY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 GERMANY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 GERMANY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 GERMANY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 GERMANY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 GERMANY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 GERMANY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 GERMANY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 GERMANY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 GERMANY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 GERMANY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 GERMANY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 GERMANY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 GERMANY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 GERMANY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 GERMANY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 GERMANY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 GERMANY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 GERMANY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 GERMANY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 GERMANY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 GERMANY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 GERMANY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 GERMANY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 GERMANY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 GERMANY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 GERMANY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 GERMANY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 GERMANY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 GERMANY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 GERMANY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 GERMANY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 GERMANY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 224 GERMANY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 GERMANY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 GERMANY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 GERMANY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 GERMANY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 GERMANY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 GERMANY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 GERMANY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 GERMANY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 GERMANY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 GERMANY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 235 GERMANY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 236 GERMANY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 GERMANY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 GERMANY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 GERMANY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 240 GERMANY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 241 GERMANY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 242 GERMANY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 UNITED KINGDOM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 244 UNITED KINGDOM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 UNITED KINGDOM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 UNITED KINGDOM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 UNITED KINGDOM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 UNITED KINGDOM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 UNITED KINGDOM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 UNITED KINGDOM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 UNITED KINGDOM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 UNITED KINGDOM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 UNITED KINGDOM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 UNITED KINGDOM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 UNITED KINGDOM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 UNITED KINGDOM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 UNITED KINGDOM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 UNITED KINGDOM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 UNITED KINGDOM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 UNITED KINGDOM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 UNITED KINGDOM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 UNITED KINGDOM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 UNITED KINGDOM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 UNITED KINGDOM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 UNITED KINGDOM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 UNITED KINGDOM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 UNITED KINGDOM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 UNITED KINGDOM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 UNITED KINGDOM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 UNITED KINGDOM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 UNITED KINGDOM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 UNITED KINGDOM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 UNITED KINGDOM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 UNITED KINGDOM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 UNITED KINGDOM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 UNITED KINGDOM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 UNITED KINGDOM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 UNITED KINGDOM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 UNITED KINGDOM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 UNITED KINGDOM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 UNITED KINGDOM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 UNITED KINGDOM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 UNITED KINGDOM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 UNITED KINGDOM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 UNITED KINGDOM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 UNITED KINGDOM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 UNITED KINGDOM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 UNITED KINGDOM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 UNITED KINGDOM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 UNITED KINGDOM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 292 UNITED KINGDOM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 UNITED KINGDOM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 UNITED KINGDOM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 UNITED KINGDOM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 UNITED KINGDOM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 UNITED KINGDOM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 UNITED KINGDOM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 UNITED KINGDOM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 UNITED KINGDOM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 UNITED KINGDOM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 UNITED KINGDOM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 UNITED KINGDOM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 UNITED KINGDOM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 UNITED KINGDOM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 UNITED KINGDOM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 UNITED KINGDOM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 308 UNITED KINGDOM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 309 UNITED KINGDOM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 310 UNITED KINGDOM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 ITALY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 312 ITALY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 313 ITALY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 ITALY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 ITALY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 ITALY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 ITALY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 ITALY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 ITALY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 ITALY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 ITALY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 ITALY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 ITALY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 ITALY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 ITALY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 ITALY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 ITALY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 ITALY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 ITALY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 ITALY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 ITALY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 ITALY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 ITALY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 ITALY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 ITALY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 ITALY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 ITALY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 ITALY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 ITALY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 ITALY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 ITALY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 ITALY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 ITALY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 ITALY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 ITALY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 ITALY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 ITALY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 ITALY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 ITALY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 ITALY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 ITALY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 ITALY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 ITALY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 ITALY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 ITALY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 ITALY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 ITALY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 ITALY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 ITALY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 360 ITALY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 ITALY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 ITALY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 ITALY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 ITALY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 ITALY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 ITALY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 ITALY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 ITALY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 ITALY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 ITALY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 371 ITALY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 ITALY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 ITALY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 ITALY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 ITALY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 376 ITALY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 377 ITALY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 378 ITALY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 FRANCE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 380 FRANCE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 FRANCE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 FRANCE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 FRANCE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 FRANCE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 FRANCE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 FRANCE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 FRANCE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 FRANCE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 FRANCE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 FRANCE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 391 FRANCE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 392 FRANCE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 FRANCE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 394 FRANCE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 FRANCE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 FRANCE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 FRANCE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 FRANCE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 FRANCE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 FRANCE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 FRANCE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 FRANCE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 FRANCE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 FRANCE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 FRANCE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 FRANCE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 FRANCE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 FRANCE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 FRANCE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 FRANCE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 FRANCE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 FRANCE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 413 FRANCE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 FRANCE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 FRANCE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 FRANCE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 FRANCE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 FRANCE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 FRANCE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 FRANCE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 421 FRANCE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 FRANCE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 FRANCE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 FRANCE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 FRANCE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 FRANCE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 FRANCE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 428 FRANCE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 FRANCE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 FRANCE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 FRANCE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 FRANCE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 433 FRANCE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 434 FRANCE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 FRANCE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 436 FRANCE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 FRANCE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 438 FRANCE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 439 FRANCE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 FRANCE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 441 FRANCE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 442 FRANCE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 FRANCE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 444 FRANCE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 445 FRANCE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 446 FRANCE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 SPAIN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 448 SPAIN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 SPAIN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 SPAIN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 SPAIN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 SPAIN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 SPAIN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 SPAIN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 SPAIN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 SPAIN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 SPAIN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 SPAIN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 SPAIN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 SPAIN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 SPAIN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 SPAIN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 463 SPAIN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 464 SPAIN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 SPAIN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 SPAIN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 SPAIN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 468 SPAIN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 SPAIN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 SPAIN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 471 SPAIN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 SPAIN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 SPAIN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 474 SPAIN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 SPAIN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 SPAIN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 SPAIN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 SPAIN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 SPAIN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 480 SPAIN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 481 SPAIN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 SPAIN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 483 SPAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 SPAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 SPAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 486 SPAIN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 SPAIN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 488 SPAIN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 489 SPAIN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 SPAIN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 491 SPAIN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 492 SPAIN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 SPAIN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 494 SPAIN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 495 SPAIN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 496 SPAIN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 497 SPAIN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 498 SPAIN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 499 SPAIN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 SPAIN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 SPAIN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 SPAIN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 503 SPAIN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 SPAIN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 SPAIN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 SPAIN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 507 SPAIN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 SPAIN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 SPAIN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 SPAIN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 SPAIN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 512 SPAIN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 513 SPAIN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 514 SPAIN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 TURKEY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 516 TURKEY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 TURKEY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 518 TURKEY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 TURKEY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 TURKEY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 521 TURKEY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 TURKEY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 TURKEY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 524 TURKEY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 TURKEY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 TURKEY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 527 TURKEY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 528 TURKEY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 TURKEY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 530 TURKEY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 531 TURKEY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 TURKEY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 533 TURKEY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 534 TURKEY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 TURKEY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 536 TURKEY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 TURKEY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 538 TURKEY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 539 TURKEY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 TURKEY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 541 TURKEY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 542 TURKEY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 TURKEY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 544 TURKEY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 545 TURKEY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 TURKEY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 547 TURKEY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 548 TURKEY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 549 TURKEY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 TURKEY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 TURKEY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 TURKEY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 553 TURKEY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 TURKEY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 TURKEY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 TURKEY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 TURKEY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 TURKEY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 TURKEY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 TURKEY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 TURKEY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 562 TURKEY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 563 TURKEY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 564 TURKEY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 TURKEY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 TURKEY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 TURKEY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 568 TURKEY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 569 TURKEY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 570 TURKEY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 571 TURKEY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 TURKEY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 TURKEY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 574 TURKEY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 575 TURKEY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 576 TURKEY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 TURKEY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 578 TURKEY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 579 TURKEY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 580 TURKEY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 581 TURKEY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 582 TURKEY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 583 RUSSIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 584 RUSSIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 585 RUSSIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 586 RUSSIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 RUSSIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 588 RUSSIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 589 RUSSIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 RUSSIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 591 RUSSIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 592 RUSSIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 RUSSIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 594 RUSSIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 595 RUSSIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 RUSSIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 597 RUSSIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 598 RUSSIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 599 RUSSIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 600 RUSSIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 RUSSIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 RUSSIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 603 RUSSIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 RUSSIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 605 RUSSIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 RUSSIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 RUSSIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 RUSSIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 RUSSIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 RUSSIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 RUSSIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 RUSSIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 613 RUSSIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 614 RUSSIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 RUSSIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 RUSSIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 RUSSIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 618 RUSSIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 RUSSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 620 RUSSIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 621 RUSSIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 RUSSIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 RUSSIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 624 RUSSIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 RUSSIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 RUSSIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 627 RUSSIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 628 RUSSIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 RUSSIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 630 RUSSIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 631 RUSSIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 632 RUSSIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 633 RUSSIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 634 RUSSIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 RUSSIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 636 RUSSIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 RUSSIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 638 RUSSIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 639 RUSSIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 RUSSIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 641 RUSSIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 642 RUSSIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 643 RUSSIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 644 RUSSIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 645 RUSSIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 RUSSIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 647 RUSSIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 648 RUSSIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 649 RUSSIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 650 RUSSIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 651 SWITZERLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 652 SWITZERLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 653 SWITZERLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 654 SWITZERLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 655 SWITZERLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 656 SWITZERLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 657 SWITZERLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 SWITZERLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 SWITZERLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 SWITZERLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 661 SWITZERLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 662 SWITZERLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 663 SWITZERLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 664 SWITZERLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 SWITZERLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 666 SWITZERLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 667 SWITZERLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 668 SWITZERLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 669 SWITZERLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 670 SWITZERLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 671 SWITZERLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 672 SWITZERLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 673 SWITZERLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 674 SWITZERLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 675 SWITZERLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 676 SWITZERLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 677 SWITZERLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 678 SWITZERLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 679 SWITZERLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 680 SWITZERLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 681 SWITZERLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 682 SWITZERLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 683 SWITZERLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 684 SWITZERLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 685 SWITZERLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 686 SWITZERLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 SWITZERLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 688 SWITZERLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 689 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 690 SWITZERLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 691 SWITZERLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 692 SWITZERLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 SWITZERLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 694 SWITZERLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 695 SWITZERLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 696 SWITZERLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 697 SWITZERLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 698 SWITZERLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 699 SWITZERLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 700 SWITZERLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 701 SWITZERLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 702 SWITZERLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 703 SWITZERLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 704 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 705 SWITZERLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 706 SWITZERLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 707 SWITZERLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 708 SWITZERLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 709 SWITZERLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 710 SWITZERLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 711 SWITZERLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 SWITZERLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 713 SWITZERLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 714 SWITZERLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 715 SWITZERLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 716 SWITZERLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 717 SWITZERLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 718 SWITZERLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 NETHERLANDS BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 720 NETHERLANDS ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 721 NETHERLANDS DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 722 NETHERLANDS ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 723 NETHERLANDS ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 724 NETHERLANDS BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 NETHERLANDS CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 726 NETHERLANDS DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 727 NETHERLANDS ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 728 NETHERLANDS CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 729 NETHERLANDS HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 730 NETHERLANDS STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 731 NETHERLANDS SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 732 NETHERLANDS ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 733 NETHERLANDS PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 734 NETHERLANDS ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 735 NETHERLANDS THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 736 NETHERLANDS OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 737 NETHERLANDS ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 738 NETHERLANDS PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 739 NETHERLANDS PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 NETHERLANDS FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 741 NETHERLANDS LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 742 NETHERLANDS STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 743 NETHERLANDS COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 744 NETHERLANDS FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 745 NETHERLANDS BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 746 NETHERLANDS PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 747 NETHERLANDS ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 748 NETHERLANDS ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 749 NETHERLANDS NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 750 NETHERLANDS NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 NETHERLANDS ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 752 NETHERLANDS TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 753 NETHERLANDS ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 754 NETHERLANDS ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 755 NETHERLANDS SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 756 NETHERLANDS SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 757 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 758 NETHERLANDS ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 759 NETHERLANDS MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 760 NETHERLANDS NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 761 NETHERLANDS ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 762 NETHERLANDS SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 763 NETHERLANDS FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 764 NETHERLANDS PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 765 NETHERLANDS THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 NETHERLANDS NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 NETHERLANDS BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 768 NETHERLANDS CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 769 NETHERLANDS PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 770 NETHERLANDS ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 771 NETHERLANDS SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 NETHERLANDS DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 774 NETHERLANDS NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 775 NETHERLANDS GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 776 NETHERLANDS DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 777 NETHERLANDS OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 778 NETHERLANDS BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 779 NETHERLANDS ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 780 NETHERLANDS INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 781 NETHERLANDS TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 782 NETHERLANDS BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 783 NETHERLANDS BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 784 NETHERLANDS BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 785 NETHERLANDS BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 786 NETHERLANDS RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 787 BELGIUM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 788 BELGIUM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 789 BELGIUM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 790 BELGIUM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 791 BELGIUM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 792 BELGIUM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 793 BELGIUM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 794 BELGIUM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 795 BELGIUM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 796 BELGIUM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 797 BELGIUM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 798 BELGIUM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 799 BELGIUM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 800 BELGIUM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 801 BELGIUM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 802 BELGIUM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 803 BELGIUM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 804 BELGIUM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 805 BELGIUM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 806 BELGIUM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 807 BELGIUM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 808 BELGIUM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 809 BELGIUM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 810 BELGIUM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 811 BELGIUM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 812 BELGIUM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 813 BELGIUM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 814 BELGIUM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 815 BELGIUM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 816 BELGIUM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 817 BELGIUM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 818 BELGIUM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 819 BELGIUM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 820 BELGIUM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 821 BELGIUM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 822 BELGIUM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 823 BELGIUM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 824 BELGIUM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 825 BELGIUM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 826 BELGIUM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 827 BELGIUM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 828 BELGIUM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 829 BELGIUM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 830 BELGIUM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 831 BELGIUM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 832 BELGIUM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 833 BELGIUM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 834 BELGIUM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 835 BELGIUM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 836 BELGIUM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 837 BELGIUM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 838 BELGIUM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 839 BELGIUM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 840 BELGIUM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 841 BELGIUM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 842 BELGIUM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 843 BELGIUM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 844 BELGIUM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 845 BELGIUM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 846 BELGIUM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 847 BELGIUM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 848 BELGIUM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 849 BELGIUM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 850 BELGIUM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 851 BELGIUM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 852 BELGIUM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 853 BELGIUM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 854 BELGIUM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 855 SWEDEN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 856 SWEDEN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 857 SWEDEN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 858 SWEDEN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 859 SWEDEN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 860 SWEDEN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 861 SWEDEN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 862 SWEDEN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 863 SWEDEN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 864 SWEDEN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 865 SWEDEN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 866 SWEDEN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 867 SWEDEN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 868 SWEDEN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 869 SWEDEN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 870 SWEDEN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 871 SWEDEN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 872 SWEDEN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 873 SWEDEN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 874 SWEDEN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 875 SWEDEN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 876 SWEDEN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 877 SWEDEN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 878 SWEDEN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 879 SWEDEN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 880 SWEDEN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 881 SWEDEN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 882 SWEDEN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 883 SWEDEN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 884 SWEDEN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 885 SWEDEN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 886 SWEDEN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 887 SWEDEN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 888 SWEDEN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 889 SWEDEN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 890 SWEDEN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 891 SWEDEN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 892 SWEDEN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 893 SWEDEN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 894 SWEDEN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 895 SWEDEN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 896 SWEDEN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 897 SWEDEN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 898 SWEDEN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 899 SWEDEN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 900 SWEDEN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 901 SWEDEN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 902 SWEDEN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 903 SWEDEN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 904 SWEDEN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 905 SWEDEN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 906 SWEDEN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 907 SWEDEN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 908 SWEDEN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 909 SWEDEN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 910 SWEDEN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 911 SWEDEN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 912 SWEDEN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 913 SWEDEN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 914 SWEDEN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 915 SWEDEN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 916 SWEDEN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 917 SWEDEN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 918 SWEDEN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 919 SWEDEN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 920 SWEDEN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 921 SWEDEN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 922 SWEDEN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 923 DENMARK BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 924 DENMARK ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 925 DENMARK DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 926 DENMARK ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 927 DENMARK ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 928 DENMARK BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 929 DENMARK CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 930 DENMARK DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 931 DENMARK ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 932 DENMARK CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 933 DENMARK HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 934 DENMARK STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 935 DENMARK SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 936 DENMARK ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 937 DENMARK PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 938 DENMARK ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 939 DENMARK THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 940 DENMARK OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 941 DENMARK ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 942 DENMARK PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 943 DENMARK PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 944 DENMARK FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 945 DENMARK LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 946 DENMARK STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 947 DENMARK COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 948 DENMARK FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 949 DENMARK BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 950 DENMARK PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 951 DENMARK ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 952 DENMARK ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 953 DENMARK NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 954 DENMARK NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 955 DENMARK ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 956 DENMARK TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 957 DENMARK ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 958 DENMARK ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 959 DENMARK SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 960 DENMARK SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 961 DENMARK TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 962 DENMARK ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 963 DENMARK MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 964 DENMARK NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 965 DENMARK ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 966 DENMARK SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 967 DENMARK FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 968 DENMARK PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 969 DENMARK THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 970 DENMARK NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 971 DENMARK BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 972 DENMARK CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 973 DENMARK PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 974 DENMARK ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 975 DENMARK SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 976 DENMARK HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 977 DENMARK DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 978 DENMARK NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 979 DENMARK GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 980 DENMARK DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 981 DENMARK OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 982 DENMARK BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 983 DENMARK ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 984 DENMARK INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 985 DENMARK TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 986 DENMARK BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 987 DENMARK BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 988 DENMARK BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 989 DENMARK BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 990 DENMARK RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 991 NORWAY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 992 NORWAY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 993 NORWAY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 994 NORWAY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 995 NORWAY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 996 NORWAY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 997 NORWAY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 998 NORWAY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 999 NORWAY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1000 NORWAY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1001 NORWAY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1002 NORWAY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1003 NORWAY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1004 NORWAY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1005 NORWAY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1006 NORWAY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1007 NORWAY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1008 NORWAY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1009 NORWAY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1010 NORWAY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1011 NORWAY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1012 NORWAY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1013 NORWAY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1014 NORWAY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1015 NORWAY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1016 NORWAY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1017 NORWAY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1018 NORWAY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1019 NORWAY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1020 NORWAY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1021 NORWAY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1022 NORWAY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1023 NORWAY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1024 NORWAY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1025 NORWAY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1026 NORWAY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1027 NORWAY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1028 NORWAY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1029 NORWAY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1030 NORWAY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1031 NORWAY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1032 NORWAY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1033 NORWAY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1034 NORWAY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1035 NORWAY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1036 NORWAY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1037 NORWAY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1038 NORWAY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1039 NORWAY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 1040 NORWAY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1041 NORWAY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1042 NORWAY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1043 NORWAY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1044 NORWAY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1045 NORWAY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1046 NORWAY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1047 NORWAY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1048 NORWAY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1049 NORWAY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1050 NORWAY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 1051 NORWAY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1052 NORWAY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1053 NORWAY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1054 NORWAY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 1055 NORWAY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 1056 NORWAY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 1057 NORWAY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 1058 NORWAY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1059 FINLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 1060 FINLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1061 FINLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1062 FINLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1063 FINLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1064 FINLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1065 FINLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1066 FINLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1067 FINLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1068 FINLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1069 FINLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1070 FINLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1071 FINLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1072 FINLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1073 FINLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1074 FINLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1075 FINLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1076 FINLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1077 FINLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1078 FINLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1079 FINLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1080 FINLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1081 FINLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1082 FINLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1083 FINLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1084 FINLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1085 FINLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1086 FINLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1087 FINLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1088 FINLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1089 FINLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1090 FINLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1091 FINLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1092 FINLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1093 FINLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1094 FINLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1095 FINLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1096 FINLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1097 FINLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1098 FINLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1099 FINLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1100 FINLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1101 FINLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1102 FINLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1103 FINLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1104 FINLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1105 FINLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1106 FINLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1107 FINLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 1108 FINLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1109 FINLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1110 FINLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1111 FINLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1112 FINLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1113 FINLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1114 FINLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1115 FINLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1116 FINLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1117 FINLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1118 FINLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 1119 FINLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1120 FINLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1121 FINLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1122 FINLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 1123 FINLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 1124 FINLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 1125 FINLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 1126 FINLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1127 REST OF EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

図表一覧

FIGURE 1 EUROPE BRANDED GENERICS MARKET: SEGMENTATION

FIGURE 2 EUROPE BRANDED GENERICS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE BRANDED GENERICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE BRANDED GENERICS MARKET: EUROPE VS REGIONAL ANALYSIS

FIGURE 5 EUROPE BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EXECUTIVE SUMMARY

FIGURE 10 STRATEGIC DECISIONS

FIGURE 11 NINE SEGMENTS COMPRISE THE EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS (2024)

FIGURE 12 EUROPE BRANDED GENERICS MARKET: SEGMENTATION

FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE EUROPE BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BRANDED GENERICS MARKET IN 2025 & 2032

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE BRANDED GENERICS MARKET

FIGURE 16 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, 2024

FIGURE 17 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)

FIGURE 18 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)

FIGURE 19 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 20 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, 2024

FIGURE 21 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 22 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)

FIGURE 23 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 24 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 25 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 26 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)

FIGURE 27 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024

FIGURE 29 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)

FIGURE 30 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)

FIGURE 31 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 32 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024

FIGURE 33 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)

FIGURE 34 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)

FIGURE 35 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE

FIGURE 36 EUROPE BRANDED GENERICS MARKET: BY END USER, 2024

FIGURE 37 EUROPE BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)

FIGURE 38 EUROPE BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)

FIGURE 39 EUROPE BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 41 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)

FIGURE 42 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)

FIGURE 43 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 EUROPE BRANDED GENERICS MARKET: SNAPSHOT (2024)

FIGURE 45 EUROPE BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)

詳細情報を見る

調査方法

データ収集と基準年分析は、大規模なサンプルサイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データマイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データモデルには、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダーシェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータスタイルでいくつでも追加できます。当社のアナリストチームは、粗い生の Excel ファイルピボットテーブル (ファクトブック) でデータを提供したり、レポートで利用可能なデータセットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

欧州ブランドジェネリック医薬品市場のレポートに含まれる主なセグメントは何ですか？

市場は欧州ブランドジェネリック医薬品市場セグメンテーション：薬物クラス別（降圧剤、ホルモン剤、代謝拮抗剤、脂質低下薬、抗てんかん薬、アルキル化剤、抗うつ剤、抗精神病薬、その他）、用途別（心血管疾患、疼痛管理・抗炎症薬、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他）、投与経路別（経口、注射、局所投与、その他）、製品タイプ別（付加価値ブランドジェネリック医薬品、商品名ジェネリック医薬品）、患者層別（成人、高齢者、小児）、エンドユーザー別（病院、診療所、在宅ケア、学術研究機関、その他）、流通チャネル別（小売薬局、病院薬局、直接入札、その他） - 2032年までの業界動向と予測に基づいて分類されます。

欧州ブランドジェネリック医薬品市場の現在の市場規模は？

欧州ブランドジェネリック医薬品市場の規模は2024年にUSD 67.97 USD Billionと推定されました。

欧州ブランドジェネリック医薬品市場の予測成長率は？

欧州ブランドジェネリック医薬品市場は2025年から2032年の予測期間にCAGR 4.5%で成長すると見込まれています。

欧州ブランドジェネリック医薬品市場の主要プレーヤーは？

市場で活動している主要プレーヤーはTeva Pharmaceutical Industries Ltd. ,Viatris Inc. ,Sandoz Group AG ,Dr. Reddy’s Laboratories Ltd. ,Sun Pharmaceutical Industries Ltd.です。

欧州ブランドジェネリック医薬品市場規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

欧州ブランドジェネリック医薬品市場規模、シェア、トレンド分析レポート

CAGR : 4.50 %

欧州のブランドジェネリック医薬品市場規模

欧州ブランドジェネリック医薬品市場分析

レポートの範囲と欧州ブランドジェネリック医薬品市場のセグメンテーション

欧州ブランドジェネリック医薬品の主要市場分析

欧州のブランドジェネリック医薬品市場動向

欧州のブランドジェネリック医薬品市場の動向

欧州ブランドジェネリック医薬品市場の範囲

欧州ブランドジェネリック医薬品市場 – 地域分析

欧州ブランドジェネリック医薬品市場の最新動向

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

Frequently Asked Questions

ISO認証

レポート

市場洞察

サポート

ソリューション

欧州ブランドジェネリック医薬品市場規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

欧州ブランドジェネリック医薬品市場規模、シェア、トレンド分析レポート

CAGR : 4.50 %

欧州のブランドジェネリック医薬品市場規模

欧州ブランドジェネリック医薬品市場分析

レポートの範囲と欧州ブランドジェネリック医薬品市場のセグメンテーション

欧州ブランドジェネリック医薬品の主要市場分析

欧州のブランドジェネリック医薬品市場動向

欧州のブランドジェネリック医薬品市場の動向

欧州ブランドジェネリック医薬品市場の範囲

欧州ブランドジェネリック医薬品市場 – 地域分析

欧州ブランドジェネリック医薬品市場の最新動向

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

Frequently Asked Questions

関連ページを閲覧する